Sakar Healthcare Ltd
Sakar Healthcare Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Sakar Healthcare Ltd Q2 FY26 key numbers
- Revenue
- Oncology plant full capacity utilization can generate revenues of around INR 1,000 crores.
As stated in Sakar Healthcare Ltd's Q2 FY26 earnings call transcript · published 15 Jul 2026. Reported figures, not investment advice.
The short version
Oncology plant full capacity utilization can generate revenues of around INR 1,000 crores (Page 15). Sakar Healthcare expects strong revenue growth driven by oncology product commercialization and marketing authorizations in EU and emerging markets from FY 2027 onwards.
From Sakar Healthcare Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Oncology plant full capacity utilization can generate revenues of around INR 1,000 crores (Page 15).
- Aspiration to achieve INR 1,000 crores top line in oncology by FY 2030 (Page 16).
- Current exports and contract agreements indicate potential of more than INR 450 crores from oncology products (Page 7).
- Targeted revenue for FY 2026 is INR 280 crores, with half-year actuals around INR 100 crores and expected ramp-up in H2 (Pages 8 and 16).
- 11 marketing authorizations approved; commercialization to boost exports primarily in Q4 FY 2026 (Page 8).
2 more points from Sakar Healthcare Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
Read what Sakar Healthcare Ltd said on margins in the Q2 FY26 call
Free account with your mobile number. We text a one-time code, no password.
Capital Expenditure Plans
- Current capex requirement is nil; existing infrastructure supports projected growth (Page 17).
- Recent capex includes approximately INR 27 crores, of which around INR 10 crores has been spent and INR 17 crores remain in capital work in progress (Page 10).
- INR 27 crores includes some capacity expansion and modifications, primarily on the oncology side (Page 8).
- No significant capex expected in FY 2027 except for maintenance-related spend (Page 10).
2 more points from Sakar Healthcare Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sakar Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Sakar Healthcare has over 50+ agreements in oncology covering more than 250 SKUs/molecules.
- Business plan includes contracts worth approximately INR 452 crores with overseas partners like Accord and Torrent.
- Over 200 dossiers have been shared with partners; 80 dossiers have been filed, and 11 marketing authorizations (MAs) have been received.
- Expecting 200+ MAs to benefit from commercialization starting FY 2027.
- The total planned dossiers exceed 250, with an estimated 100 marketing authorizations expected after a 20% deduction.
2 more points from Sakar Healthcare Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Sakar Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹87 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sakar Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
- Emcure Pharmaceuticals Ltd (Q2 FY26)
Emcure Pharmaceuticals delivered a strong Q2 FY26 with 25% PAT growth, reporting highest quarterly profit of INR 251 crores. Key concall takeaways from Emcure…
Arthneeti Pro · Annual
Sakar Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sakar Healthcare Ltd Q2 FY26 results?
Oncology plant full capacity utilization can generate revenues of around INR 1,000 crores (Page 15). Sakar Healthcare expects strong revenue growth driven by oncology product commercialization and marketing authorizations in EU and emerging markets from FY 2027 onwards.
What is Sakar Healthcare Ltd share price analysis?
Sakar Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 54.0 with a market cap of ₹1,949 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sakar Healthcare Ltd planning capital expenditure?
Current capex requirement is nil; existing infrastructure supports projected growth (Page 17).
Keep Sakar Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.